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Abstract
Background: Myofibroblasts play a major role in the synthesis of extracellular matrix (ECM) and the stimulation of
these cells is thought to play an important role in the development of silicosis. The present study was undertaken
to investigate the anti-fibrotic effects of dibutyryl-cAMP (db-cAMP) on rats induced by silica.
Methods: A HOPE MED 8050 exposure control apparatus was used to create the silicosis model. Rats were randomly
divided into 4 groups: 1)controls for 16 w; 2)silicosis for 16 w; 3)db-cAMP pre-treatment; 4) db-cAMP post-treatment.
Rat pulmonary fibroblasts were cultured in vitro and divided into 4 groups as follows: 1) controls; 2) 10−7mol/L
angiotensin II (Ang II); 3) Ang II +10−4 mol/L db-cAMP; and 4) Ang II + db-cAMP+ 10−6 mol/L H89. Hematoxylin-eosin
(HE), Van Gieson staining and immunohistochemistry (IHC) were performed to observe the histomorphology of lung
tissue. The levels of cAMP were detected by enzyme immunoassay. Double-labeling for α-SMA with Gαi3, protein
kinase A (PKA), phosphorylated cAMP-response element-binding protein (p-CREB), and p-Smad2/3 was identified by
immunofluorescence staining. Protein levels were detected by Western blot analysis. The interaction between CREB-
binding protein (CBP) and Smad2/3 and p-CREB were measured by co-immunoprecipitation (Co-IP).
Results: Db-cAMP treatment reduced the number and size of silicosis nodules, inhibited myofibroblast differentiation,
and extracellular matrix deposition in vitro and in vivo. In addition, db-cAMP regulated Gαs protein and inhibited
expression of Gαi protein, which increased endogenous cAMP. Db-cAMP increased phosphorylated cAMP-response
element-binding protein (p-CREB) via protein kinase A (PKA) signaling, and decreased nuclear p-Smad2/3 binding with
CREB binding protein (CBP), which reduced activation of p-Smads in fibroblasts induced by Ang II.
Conclusions: This study showed an anti-silicotic effect of db-cAMP that was mediated via PKA/p-CREB/CBP
signaling. Furthermore, the findings offer novel insight into the potential use of cAMP signaling for
therapeutic strategies to treat silicosis.
Keywords: Silicosis, Myofibroblast, CAMP, PKA, CREB, Smad
* Correspondence: fangyang990404@sina.com
†Equal contributors
1Basic Medical College, Hebei Medical University, No. 361 Zhongshan Road,
Shijiazhuang city, Hebei province, China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Liu et al. Respiratory Research  (2017) 18:38 
DOI 10.1186/s12931-017-0523-z
Background
Silicosis is a fibrotic disease caused by inhalation of
crystalline silica dust and the subsequent formation of
silicotic lesions and extracellular matrix (ECM) depos-
ition by activated myofibroblasts [1–3]. Myofibroblasts
are α-smooth muscle actin (α-SMA)-expressing cells
that secrete ECM components and originate from di-
verse sources that depend on physiological stimuli [4].
Ang II, a major renin-angiotensin peptide can in-
crease expression of transforming growth factor-β
(TGF-β) and promote an Ang II/TGF-β1 “autocrine
loop,” which initiates a fibrogenic signaling pathway
[5]. Accumulating evidence suggests that TGF-β/Smad
signaling is a mediator of pro-fibrotic effects of Ang
II and promotes myofibroblast differentiation [6]. Ang
II has been suggested to be involved in lung inflam-
mation via release of pro-inflammatory cytokines [7],
which induce alveolar epithelial cell apoptosis [8].
Additional studies have shown that Ang II is up-
regulated in serum and lung tissue in a silicosis rat
model [3]. Furthermore, treatment with ACE inhibi-
tors and Ang II receptor blockers have been shown
to improve pulmonary fibrosis [9, 10]. Collectively,
these findings suggest that Ang II signaling has a crit-
ical role in the pathogenesis of lung fibrosis.
In previous work, a preliminary proteomic profile ana-
lysis indicated that cAMP signaling might have anti-
silicotic effects [11]. cAMP is generated by adenylyl cy-
clase (AC) in response to activation of stimulatory G
protein (Gs) or by blocking inhibitory G protein (Gi),
and it is degraded by phosphodiesterase (PDE). Increases
in cAMP inhibit fibroblast proliferation and ECM syn-
thesis, which have anti-fibrotic effects in vitro and in
vivo [4, 12]. A PDE inhibitor (roflumilast) [13], an AC
activator (forskolin) [14], or an exogenous prostaglandin
E2, such as aminophylline, have been shown to have
anti-fibrotic effects as well [15]. In addition, cAMP con-
trols inhibition of fibroblast activation and myofibroblast
transition. Studies suggest that increasing concentrations
of cAMP not only prevent cardiac fibroblast-to-
myofibroblast transformation, but also reverse the pro-
fibrotic myofibroblastic phenotype [14, 16]. Further-
more, over-expression of PDE2 in cardiac fibroblasts
reduced basal and isoprenaline-induced cAMP synthesis,
and this effect was sufficient to induce fibroblast-to-
myofibroblast conversions even without exogenous pro-
fibrotic stimuli [17].
Dibutyryl-cAMP (db-cAMP) is a cell permeable
analogue of cAMP that can prevent acute pulmonary
vascular injury induced by endotoxin [18]. It has also
been shown to attenuate ischaemia/reperfusion injury
in rat lungs [19], and inhibit fibroblast proliferation
and collagen production [20, 21]. PKA, the classical
cAMP effector, can phosphorylate cAMP-response
element-binding protein (CREB) at serine 133, and
as such is associated with co-activation of the CREB
binding protein (CBP) and transactivation of cAMP-
responsive genes [22–25]. Increased cAMP levels has
been shown to abolish TGF-β1-induced interaction
of Smad3 with CBP, and to decrease ECM [22, 24].
However, how db-cAMP/PKA/CREB/CBP signaling
attenuates silicosis is unknown.
Here, we investigated the anti-fibrotic effect of db-
cAMP in a silicosis rat model and in myofibroblasts
induced by Ang II, and studied the regulatory effect
of db-cAMP upon Gαs and Gαi. We also examined
the ability of db-cAMP to regulate the interaction of
CBP with Smad2/3 through PKA/CREB signaling. The
results of the studies implicate an important role for
cAMP signaling in silicosis, which could lead to de-
velopment novel therapies for treatment of silicosis.
Methods
Animal Experiments
All animal experiments were approved by the North China
University of Science and Technology Institutional Animal
Care and Use Committees (2013-038). Male Wistar rats
(3 weeks-of-age) were from Vital River Laboratory Animal
Technology Co. Ltd. (SCXY 2009-0004, Beijing, China). A
HOPE MED 8050 exposure control apparatus (HOPE In-
dustry and Trade Co. Ltd, Tianjin, China) was used to cre-
ate the silicosis model (Additional file 1: Figure S1). This
system can be set to a certain dust concentration and it is a
non-invasive instrument for allowing animal inhalation.
Settings were as follows: exposure chamber volume 0.3 m3,
cabinet temperature 20–25 oC, humidity 70–75%, pressure
-50 to + 50 Pa, oxygen concentration 20%, flow rate of SiO2
(5 um silica particles, s5631, Sigma-Aldrich) 3.0–3.5 ml/
min, dust mass concentration in the cabinet 2000 mg/m3,
and each animal inhaled for 3 h per day. db-cAMP (10 mg/
kg/d) or 0.9% saline was given by subcutaneous injection.
A preliminary experiment showed that cellular le-
sions are observed in rats exposed to silica for 4 w,
and confluent multi-nodular or diffuse distribution of
cellular lesions is found in rats exposed to silica for
16 w (Additional file 2: Figure S2). Based on the re-
sults of the preliminary experiment, rats were ran-
domly divided into 4 groups: 1)controls for 16 w
(treated with 0.9% saline for 16 w); 2)silicosis for 16
w (treated with 0.9% saline 48 h before SiO2 inhaling,
and then continued treatment for 16 w); 3)db-cAMP
pre-treatment (treated with db-cAMP 48 h before in-
haling of SiO2, and then continued for 16 w); 4) db-
cAMP post-treatment (inhaling of SiO2 and treated
with 0.9% saline for 4 w and db-cAMP for another
12 w). Silicotic rats treated with or without db-cAMP
were all exposed to silica for 16 weeks.
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Cell culture
Lung fibroblasts were isolated from minced tissue and
plated on 25 cm2 plates in DMEM (BI-SH0019, BI, Kib-
butz Beit-Haemek, Israel) medium containing 10% FBS
(10099141, Gibco, Thermo Fisher Scientific) and 1%
penicillin-streptomycin. Cells were cultured in a humidi-
fied atmosphere of 5% CO2 and 95% air at 37
oC. Cells
at 80% confluence were cultured in FBS-free DMEM
medium for 24 h, when most cells were quiescent. Next,
cells were divided into four groups and were cultured
for 24 h as follows: 1) controls; 2) 10−7mol/L Ang II
(A9525, Sigma-Aldrich); 3) Ang II +10−4 mol/L db-
cAMP: db-cAMP treatment was started 1 h before Ang
II stimulation; and 4) Ang II + db-cAMP+ 10−6 mol/L
H89 (10010556, Cayman): H89 treatment was started
1 h before db-cAMP treatment.
Histological analysis
The right lower lungs were fixed in 4% paraformalde-
hyde, paraffin embedded, and then sectioned for patho-
physiological observation. Lung tissue slides were
stained with hematoxylin-eosin (HE) to assess fibrosis.
Van Gieson (VG) staining was used to measure collagen
fiber deposition. The number and size/area of silicosis
nodules were counted by CellSense software and Olym-
pus DP80 system. Based on the VG staining, the area of
collagen deposition ≥50% in a silicotic nodule was de-
fined as a score of “2”, and an area <50% was defined as
a score of “1”. The silicotic area (product of area and
collagen score) and the number of silicotic nodules were
homogenized by the total area of lung section.
Immunohistochemistry (IHC)
Paraffin-embedded sections of lung tissue were assessed
with IHC. Endogenous peroxidases were quenched with
0.3% H2O2, and antigen retrieval was performed using a
high-pressure method on dewaxed tissue sections. Sam-
ples were then incubated with primary antibodies
against α-SMA (ab32575, Eptomics, Burlingame, CA)
and p-CREB (ab32096, Abcam) overnight at 4 °C,
followed by incubation with a secondary antibody (PV-
6000, Beijing Zhongshan Jinqiao Biotechnology Co. Ltd,
China) at 37 °C for 20 min. Immunoreactivity was visu-
alized with DAB (ZLI-9018, ZSGB-BIO, Beijing, China).
Brown staining was considered positive.
Immunofluorescence
Co-staining was performed on lung tissue sections and fi-
broblasts. Samples were incubated in 10% donkey serum
(92590, Temecula, CA) for 30 min at 37 °C. After co-
incubation overnight at 4 °C with Gαi3 (sc-365422, Santa
Cruz Biotechnology, Dallas, TX)/α-SMA, PKA(ADI-KAS-
PK017, Enzo, Farmingdale, NY)/α-SMA, p-CREB/α-SMA
and p-Smad2/3 (ART1568, Antibody Revolution, San
Diego, CA)/α-SMA, sections were incubated with products
from Novex (Life Technologies, Frederick, MD): donkey
anti-rabbit IgG (H + L) FITC (A16024), donkey anti-mouse
IgG (H + L) TRITC (A16016), Alexa Fluor 647 donkey
anti-goat IgG (H+ L) (A21447) or donkey anti-rabbit IgG
(H + L) TRITC (A16028) and donkey anti-mouse IgG (H +
L) FITC (A16018) for 60 min each at 37 °C in blocking buf-
fer. Nuclei were stained with DAPI (14285, Cayman, Ann
Arbor, MI) for 5 min. Cells or tissues were visualized under
an Olympus DP80 microscope and were analyzed with
image software (Cell Sens 1.8, Olympus Corporation,
Germany).
Western blot
The lung tissue or cells were lysed in RIPA buffer (1%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM
NaCl, 1 mM EDTA, and 50 mM Tris-HCl, pH 7.5) con-
taining a protease inhibitor cocktail (P2714-1BTL,
Sigma-Aldrich, St. Louis, MO). Protein concentrations
in supernatants were measured with a Bradford assay
(PC0020, Solarbio, Beijing, China). Protein samples
(20 μg/lane) were separated with 10% SDS-PAGE and
electrophoretically transferred to PVDF membranes. The
membranes were then blocked with Tris-buffered solu-
tion with 0.1% Tween supplemented with 5% fat-free
milk, and incubated overnight at 4 oC with primary anti-
body against collagen type I (Col I) (ab34710, Abcam,
Cambridge, UK), Fibronectin (Fn) (ab45688, Eptomics,
Burlingame, CA), α-SMA, Gαs (sc-135914, Santa Cruz
Biotechnology, Dallas, Texas), Gαi2 (sc-7276, Santa Cruz
Biotechnology, Dallas, TX), Gαi3, PKA, p-CREB, CREB
(ab32515, Abcam, Cambridge, UK), p-Smad2/3, total-
Smad2/3 (3308791, BD Biosciences, San Jose, CA) or
CBP (ab2832, Abcam, Cambridge, UK). The membranes
were then probed with a peroxidase-labeled affinity-
purified antibody to rabbit/mouse IgG (H + L) (074–
1506/074–1806, Kirkegard and Perry Laboratories, Gai-
thersburg, MD) and peroxidase-labeled affinity-purified
antibody to goat IgG (H + L) (14–13-06, Kirkegard and
Perry Laboratories, Gaithersburg, MD). Target bands
were visualized by the addition of ECLTM Prime Western
Blotting Detection Reagent (RPN2232, GE Healthcare,
Hong Kong, China). Results were normalized with β-
action (sc-47778, Santa Cruz Biotechnology) or GAPDH
(sc-25778, Santa Cruz Biotechnology).
Co-immunoprecipitation (Co-IP)
For performance of Co-IP, lung fibroblast cells were
lysed with RIPA buffer and centrifuged at 13,000 × g for
10 min at 4 oC. The supernatants were collected, and
immunoprecipitation was performed with an antibody to
CBP, and immune complexes were captured using Pro-
teinA/G-agarose beads (SC-2003, Santa Cruz Biotech-
nology), according to the manufacturer’s instructions.
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Protein was eluted by boiling in 1× concentrated sample
buffer and analyzed by Western blot.
Enzyme immunoassay (EIA)
The levels of cAMP in cellular and lung tissue were de-
termined by using a cAMP EIA kit (581001, Cayman,
Ann Arbor, MI, USA), according to the manufacturer’s
instruction. Each assay point was performed in triplicate.
The content of cAMP was calculated according to the
standard curve.
Statistical analysis
Data are presented as means ± SEM. Comparisons be-
tween multiple independent groups were performed with
one-way ANOVA, followed by a post hoc analysis with
the Bonferroni test using SPSS13.0 software. Group dif-
ferences with p-values < 0.05 indicate a statistically sig-
nificant difference.
Results
Db-cAMP reduced expression of ECM and myofibroblast
differentiation in rats exposed to silica and in fibroblasts
induced by Ang II
HE and Van Gieson staining (Fig. 1a, b and d) revealed
that db-cAMP pre- and post-treatment reduced the
number and size of silicotic nodules, as well as the accu-
mulation of collagenous fibers. IHC staining of tissue in-
dicated positive expression of α-SMA was marked in
myofibroblasts, which were surrounded by macrophages
and unevenly distributed in the interstitial fibrotic area
(Fig. 1c). In addition, Western blot analysis demon-
strated that Fn, Col I and α-SMA expression were in-
creased in the silica inhalation for 16 W group, as
compared with controls (Fig. 1e). Intriguingly, pre-
treatment with db-cAMP reduced these fibrotic changes,
and db-cAMP post-treatment had the same effect.
After Ang II induction, the synthesis of Fn, Col I and
α-SMA were significantly increased in cultured lung fi-
broblasts, as compared to controls (Fig. 1f ). In contrast,
pretreatment with db-cAMP reduced Fn, Col I and α-
SMA expression. Specifically blocking the PKA signal by
H89 reduced the effect of db-cAMP on Ang II.
Db-cAMP regulated Gαs/Gαi, cAMP contents in silicosis
and in myofibroblasts induced by Ang II
As shown in Fig. 2, co-expression of Gαi3 and α-SMA
were increased significantly in silicotic nodules and
interstitial fibrotic regions, as compared to controls. In
the area of interstitial fibrosis or alveolar wall broaden-
ing, there was significant Gαi3 protein positive expres-
sion. Pre- or post-treatment with db-cAMP decreased
expression of both Gαi3 and α-SMA. As shown in
Fig. 3a, Western blot analysis confirmed that db-cAMP
pre- or post-treatment decreased the expression of Gαi2
and Gαi3 in silicotic lung tissue, while up-regulating
Gαs, cAMP.
To investigate whether Gαs/Gαi proteins were in-
volved in myofibroblast differentiation in vitro, we
Fig. 1 Myofibroblast differentiation and ECM deposition is regulated by db-cAMP. a Lung tissue stained with HE staining; b Lung tissue stained
with Van Gieson staining; c Immunohistochemical measurement of α-SMA expression in rat lung silicosis tissue; d Percentage of silicotic nodule
area and number of silicotic nodule; e Fn, Col I and α-SMA expression in lung tissue (Western blot). Data are means ± SEM; n = 6 independent ex-
periments; f Fn, Col I and α-SMA expression in fibroblasts (Western blot). Data are means ± SEM; n = 6 independent experiments
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Fig. 2 The Co-expression of Gαi3 and α-SMA in rat silicosis lung tissue is regulated by db-cAMP (immunofluorescence)
Fig. 3 The expression of Gαs/Gαi protein and endogenous cAMP level is regulated by db-cAMP. a Gαs, Gαi2, Gαi3 and cAMP expression in rat
lung tissue (Western blot, EIA); Data are means ± SEM; n = 6 independent experiments; b Gαs, Gαi2, Gαi3 and cAMP expression in fibroblasts
(Western blot, EIA). Data are means ± SEM; n = 6 independent experiments
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quantified expression of Gαs, Gαi2, and Gαi3 in Ang II-
treated lung fibroblasts. As shown in Fig. 3b, Western
blot analysis demonstrated that Ang II treatment signifi-
cantly reduced Gαs, while enhancing expression of Gαi2
and Gαi3. Furthermore, pre-treatment with db-cAMP
increased Gαs and reduced the up-regulation of Gαi2
and Gαi3 induced by Ang II. Correspondingly, the level
of cAMP in fibroblasts was significantly increased. Fi-
nally, all of the effects of db-cAMP were inhibited by the
PKA signaling inhibitor, H89 (Fig. 3b).
Db-cAMP inhibited myofibroblast differentiation by
promoting nuclear translocation of p-CREB via PKA
signaling
Since PKA is a classic cAMP effector, we next investi-
gated whether myofibroblast differentiation could be
inhibited by PKA/CREB signaling. As shown in Fig. 4a,
immunofluorescent staining revealed that PKA and p-
CREB were significantly decreased in Ang II-induced fi-
broblasts, and this effect was accompanied by up-
regulation of α-SMA in the cytoplasm, as compared with
controls. Furthermore, positive expression of p-CREB
was observed in nuclei after fibroblast treatment with
db-cAMP, and decreased in the Ang II group or H89
treatment group. In line with the immunofluorescent
data, Western blot results confirmed that db-cAMP
treatment inhibited the Ang II-induced down-regulation
of PKA and p-CREB, and this effect was reversed with
by H89 (Fig. 4b).
We next measured expression and localization of p-
CREB in the silicosis model using IHC staining. Positive
expression of p-CREB was observed in the nucleus of
normal lung tissue, with no staining observed in silicotic
nodules (Fig. 5a). Furthermore, Western blot results
showed that the levels of PKA and p-CREB were signifi-
cantly reduced in the silicosis group (Fig. 5b), while pre-
Fig. 4 Activation of db-cAMP on PKA/p-CREB signaling in vitro. a Co-expression of PKA/α-SMA and p-CREB/α-SMA in fibroblasts (immunofluores-
cence; red: α-SMA; green: PKA and p-CREB; blue: DAPI); b PKA and p-CREB expression in fibroblasts (Western blot); Data are means ± SEM; n = 6
independent experiments
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or post-treatment with db-cAMP promoted expression
of both PKA and p-CREB.
Db-cAMP inhibition of myofibroblast differentiation is
dependent upon p-CREB/CBP signaling interference with
Smad2/3 signaling
Smad2/3 is a major pro-fibrotic signaling molecule that
can activate α-SMA promoter activity and promote
myofibroblast differentiation. Examination of p-Smad2/3
by immunofluorescent staining and Western blot ana-
lysis showed that it was significantly increased in the sili-
cotic rat model and in fibroblasts induced with Ang II
(Figs. 6 and 7a and b). Treatment with db-cAMP inhib-
ited up-regulation of p-Smad2/3 in vivo and in vitro.
Blocking PKA signaling by H89 prevented inhibition of
db-cAMP in Ang II-induced myofibroblasts. With Co-IP
analysis (Fig. 7c), we noted an interaction of CBP with
p-CREB or p-Smad2/3. Co-IP data from fibroblast ly-
sates with anti-CBP antibodies indicated increased ex-
pression of p-Smad2/3, and down-regulation of p-CREB
in fibroblasts induced with Ang II. Treatment with db-
cAMP promoted association of p-CREB and inhibited
association of p-Smad2/3 with CBP. Thus, p-CREB/CBP
interactions inhibited binding of p-Smad2/3 to CBP and
inhibited p-Smad2/3 nuclear translocation.
Discussions
Over the past decade, tracheal instillation of silica dust
has been extensively used as a silicosis model to reveal
the possible mechanism of the occurrence and develop-
ment of silicosis [3, 26, 27]. In the current study, our
rat model was created using silica that was inhaled
from a HOPE MED8050 exposure control apparatus,
which allows greater control and more closely approxi-
mates exposure and development of silicosis in
humans. After inhalation of SiO2 for 4 w, silicotic nod-
ules were visible in lung tissue and these increased by 8
w. Fibrous and cellular silicotic nodules with diffuse
interstitial fibrosis were observed in rats at 16 w. Based
on the these results, inhalation of SiO2 for 16 w was
used for further evaluation of the anti-fibrotic effects of
db-cAMP. Further characterization with IHC revealed
that α-SMA-positive expressing myofibroblasts sur-
rounded macrophages and were irregularly distributed
in interstitial fibrotic areas, further confirming the ro-
bustness of the silicosis model. It is well known that
RAS is a key mediator of lung fibrosis pathogenesis and
that Ang II potently induces fibrosis [3, 28, 29]. In
agreement, treatment of fibroblasts with Ang II in our
study markedly increased expression of Fn, Col I and
α-SMA. Thus, the rat silicosis model used in our study
was characterized by robust ECM deposition and myo-
fibroblast differentiation, which was mediated at least
in part, by RAS signaling activation.
Increase in cAMP has been previously shown to in-
hibit fibroblast proliferation and ECM synthesis, and to
be correlated with anti-fibrotic effects in vitro and in
vivo [4, 12]. Furthermore, cAMP was previously shown
to protect against pulmonary fibrosis induced by bleo-
mycin, chronic obstructive pulmonary disease, and ex-
perimental acute lung injury [30–32]. In the current
study, the results showed that treatment with db-cAMP
Fig. 5 The expression of PKA/p-CREB protein is regulated by db-cAMP in vivo. a p-CREB expression in silicotic rat lung tissue (IHC); b PKA and p-
CREB expression in rat silicotic lung tissue (Western blot); Data are means ± SEM; n = 6 independent experiments
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reduced the number and size of silicotic nodules and
collagenous fibers, and inhibited ECM synthesis and
myofibroblast differentiation in vitro and in vivo. Also,
db-cAMP promoted expression of Gαs protein and
inhibited expression of Gαi protein, which increased en-
dogenous cAMP. From a functional standpoint, previous
work has shown that Gαi2 and Gαi3 can contribute to
redundant and overlapping inflammation in an experi-
mental model of immune complex-induced inflamma-
tion [33]. Furthermore, Gαi2-deficient mice had less
recruitment of macrophages in lipopolysaccharide-
induced lung injury, and decreased RAW 264.7 cell mi-
gration and motility [34]. In contrast, Gαs has been
shown to be required for adenosine-induced barrier en-
hancement effects in human pulmonary artery endothe-
lial cells [35]. Thus, the balance of Gαs/Gαi in lung
fibrosis may regulate cAMP, ECM, myofibroblast differ-
entiation, inflammation and endothelial cell barrier
function.
Mechanistically, our study demonstrated a dramatic
down-regulation of cAMP/PKA/p-CREB signaling in the
silicosis model and in induced fibroblasts, and this effect
was significantly reduced with db-cAMP treatment. Fur-
thermore, the PKA inhibitor H89 prevented the anti-
fibrotic effects of db-cAMP. These findings suggest that
regulation of cAMP/PKA/p-CREB signaling can have
Fig. 6 The expression of p-Smad2/3 protein is regulated by db-cAMP in vivo. a Co-expression of p-Smads/α-SMA in lung tissue (immunofluores-
cence; red: p-Smad2/3; green: α-SMA; blue: DAPI); bThe expression of p-Smad2/3 and Smad2/3 in vivo (Western blot); Data are means ± SEM; n = 6
independent experiments
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important anti-fibrotic effects in silicosis. In support of
this possibility, another study found that the antitussive
drug, nosacpine stimulated a rapid and profound activa-
tion of PKA in a pulmonary fibrosis model, which corre-
lated with significant anti-fibrotic effects in vitro and in
vivo [36]. In another study, Prkar1a null primary mouse
embryonic fibroblasts, which display constitutive PKA
signaling, had down-regulated vimentin and α-SMA ac-
companied with up-regulation of E-cadherin, suggesting
that activation of PKA signaling promoted mesenchymal
to epithelial transition [37].
Accumulating evidence indicates that Smad2/3 is
extensively activated in fibrotic disease and in animal ex-
periments, regulating various genes including α-SMA
and Col I [38, 39]. Previous studies confirm that Ang II
is critical to pathological organ remodeling via activating
Smad signaling to cause pro-fibrotic effects by promot-
ing myofibroblast differentiation and excessive synthesis
and deposition of ECM [40–44]. Herein, we observed
that nuclear expression of p-Smad2/3 in vitro and in
vivo was related to myofibroblast differentiation and
ECM synthesis, which was reduced by db-cAMP via
PKA signaling. CREB is a well-known transcription
factor of the basic leucine zipper family and upon activa-
tion it promotes interactions with co-activators such as
CBP, E1A binding protein p300 (P300), and CREB-
regulated transcription co-activator 2 (CRTC) by adapt-
ing DNA-binding and transcriptional activation [45, 46].
Interestingly, CBP is required for a multi-protein com-
plex among p-Smad3, β-catenin and CBP at the
Fig. 7 Interaction of p-CREB and p-Smad2/3 binding with CBP is regulated by db-cAMP. a Co-expression of p-Smads/α-SMA in fibroblasts (im-
munofluorescence; red: p-Smad2/3; green: α-SMA; blue: DAPI); b The expression of p-Smad2/3 in vitro (Western blot); Data are means ± SEM; n = 6
independent experiments; c p-CREB and p-Smad2/3 binding with CBP measured by co-IP, Data are means ± SEM, n = 3 independent experiments
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promoter to regulate α-SMA expression in RLE-6TN
cells treated with TGF-β1 [23]. Moreover, increasing
intracellular cAMP levels can phosphorylate CREB, and
recruiting CBP in the nucleus from Smad proteins in-
hibits the effects of TGF-β1/Ang II on fibroblasts [22,
24, 47]. In our study, Co-IP showed that db-cAMP in-
creased p-CREB, while down-regulating p-Smad2/3
binding to CBP, which reduced activation of p-Smads in
induced fibroblasts. IHC data further showed that posi-
tive nuclear expression of p-CREB occurred chiefly in
normal lung tissue, and expression was lost in silicotic
nodules. In contrast, positive expression of p-smad2/3
was mainly located in silicotic nodules. p-CREB location
suggested that it might appear in multiple cell types and
regulate an anti-fibrotic process. Thus, the results of our
study provides evidence that cAMP has anti-fibrotic ef-
fects in vitro and in vivo, and that these effects depend
on PKA/p-CREB signaling by disturbing p-Smad2/3
binding with CBP, and inhibiting myofibroblast differen-
tiation in a model of silicosis (Fig. 8).
Conclusions
Taken together, in the present study, we provide evi-
dence that db-cAMP has anti-fibrotic effects in vitro and
in vivo. The effects were dependent on PKA/p-CREB
signaling to disrupt p-Smad2/3 binding with CBP, and
ultimately result in inhibition of myofibroblast differenti-
ation in silicosis.
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Additional file 1: Figure S1. The HOPE-MED 8050 exposure control ap-
paratus. A) barrier system; B) silica inhalation system; C) waste disposal
system (JPG 2785 kb)
Additional file 2: Figure S2. The morphological observation of rat
exposed to silica. (JPG 4540 kb)
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Fig. 8 Proposed Mechanism of cAMP Anti-Fibrotic Effects. Anti-
fibrotic effects of cAMP are proposed to involve 1) increased PKA
and p-CREB, 2) down-regulation of p-Smad2/3 binding to CBP, 3)
concomitant reduced activation of p-Smads and the Smad-induced
genes, Collagen I, Fn and α-SMA in induced fibroblasts, and 4) a re-
sultant inhibition of myofibroblast differentiation
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